Latest News

Stay up-to-date on the latest developments in the fields of vitreo-retinal disease treatments and ophthalmology in general. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with ThromboGenics associates. Be sure to check in regularly for the latest ThromboGenics’ press releases or just subscribe to our mailing list to receive regular updates.

Haven’t found what you’re looking for? Take a look at our press release history.



  • 15 Mar 2018
    ThromboGenics Business Update – FY 2017
  • 30 Jan 2018
    Disclosure in accordance with Belgian Law of 2 May 2007
  • 26 Jan 2018
  • 8 Dec 2017
    ThromboGenics - Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy Discontinued due to Slow Recruitment Rate
  • 8 Nov 2017
    ThromboGenics Strengthens Leadership Team
  • 20 Oct 2017
    ThromboGenics Business Update – Q3 2017
  • 9 Oct 2017
    ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR
  • 27 Sep 2017
    ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting
  • 21 Sep 2017
    ThromboGenics Provides Business and Clinical Update at European and US Investor Meetings
  • 18 Sep 2017
    ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)
  • 7 Sep 2017
    ThromboGenics Business Update – H1 2017
  • 1 Sep 2017
    ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB
  • 16 Aug 2017
    New Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 in Boston
  • 10 Jul 2017
    ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement
  • 15 Jun 2017
    Thomas Clay Appointed Chairman of the Board of Directors